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Minimally invasive surgery (MIS) can be considered as the greatest surgical innovation 
over the past 30 years. It revolutionized surgical practice with well-proven advantages 
over traditional open surgery: reduced surgical trauma and incision-related complications, 
such as surgical-site infections, postoperative pain and hernia, reduced hospital stay, 
and improved cosmetic outcome. Nonetheless, proficiency in MIS can be technically 
challenging as conventional laparoscopy is associated with several limitations as the 
two-dimensional (2D) monitor reduction in-depth perception, camera instability, limited 
range of motion, and steep learning curves. The surgeon has a low force feedback, which 
allows simple gestures, respect for tissues, and more effective treatment of complica-
tions. Since the 1980s, several computer sciences and robotics projects have been set 
up to overcome the difficulties encountered with conventional laparoscopy, to augment 
the surgeon’s skills, achieve accuracy and high precision during complex surgery, and 
facilitate widespread of MIS. Surgical instruments are guided by haptic interfaces that 
replicate and filter hand movements. Robotically assisted technology offers advantages 
that include improved three-dimensional stereoscopic vision, wristed instruments that 
improve dexterity, and tremor canceling software that improves surgical precision.
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BACKGROUND AND HiSTORY
Robotic applications to surgery started in 1970s as military projects endorsed by the National 
Aeronautics and Space Administration (NASA) and funded by the Defense Advanced Research 
Project Administration (DARPA) in order to replace the surgeon’s physical presence and provide 
care to astronauts or to soldiers in battlefields (1). From middle 1980s to late 1990s, the first genera-
tion of robots was used to perform image-guided precision tasks, but these platforms were limited 
by basic computer interfaces and required a lengthy preoperative planning. The second and cur-
rent generation of real-time tele-manipulators was set in a master–slave configuration, in which 
the master unit (the surgeon’s console) controls a separate slave unit formed by robotic arms with 
multiple degrees of freedom. Two main tele-manipulators were developed and approved by the US 
Food and Drug Administration (FDA): the Zeus® system (Computer Motion, Goleta, CA, USA) and 
the da Vinci® Surgical System (Intuitive Surgical, Sunnyvale, CA, USA). In 2003, Intuitive Surgical 
acquired Computer Motion, which created a situation of corporate monopoly in the surgical robotics 
market, a situation that has not changed to date. After the merger of Computer Motion and Intuitive 
Surgical, development of the Zeus® robot was discontinued in favor of the da Vinci® system, which 
was equipped with a compact platform moving on wheels, three to four robotic operating arms and 
a stereoscopic immersive camera being able to give a 10-fold magnified view and under control 
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by the surgeon, for a stable and precise navigation. Ergonomics 
and  dexterity are greatly improved by handles reproducing 
human hand movements by Endowrist® technology. The da 
Vinci® Surgical System has been upgraded over recent years 
to include additional features, such as near-infrared technol-
ogy, and to facilitate setup. The latest generation da Vinci Xi™ 
system, released in 2014, is less bulky, and its arms are thinner 
and arranged in a more ergonomic way, enabling multiquadrant 
procedures without the need to replace the system. However, lack 
of force feedback is still one of the major technical drawbacks.
PeNeTRANCe OF ROBOTiC-ASSiSTeD 
SURGeRY iN GYNeCOLOGY
At present, more than 3,200 robotic platforms have been installed 
worldwide (2,223 United States, 549 Europe, and 494 Rest of 
World). Approximately 570,000 da Vinci® procedures performed 
in 2014, up to 9% from 2013 were performed. Only 4 years after 
its clearance for gynecologic applications, 24% of US gynecologist 
oncologists reported using robotic-assisted surgery, with 66% 
indicating that they planned to increase their use of the technol-
ogy in the next year. The 95% of gynecologic oncology fellows 
have a robotic platform at their institutions, and 95% were trained 
to use it (2). According to the same study, 74% of fellows were 
trained to perform robotic-assisted lymph node dissection, and 
44% performed radical hysterectomies (3).
CLiNiCAL CONSiDeRATiONS iN 
GYNeCOLOGY
Since FDA approval of da Vinci® surgical system for use in 
gynecologic surgery in 2005, the growth of robotic procedures has 
exploded in recent years. Intuitive Surgical reports that surgeons 
performed 422,000 operations with its system in the United States 
in 2013, a 12% increase over 2012 volume. Hysterectomy has been 
the largest and fastest growing procedure for robotic surgery on 
the da Vinci® system, having grown 36% in 2 years, to 191,000 
cases in 2013. Nonetheless, even though robotic-assisted surgery 
has been shown to be safe and feasible in gynecological surgery 
procedures, evaluation in randomized controlled trials comparing 
it with conventional laparoscopy is limited, and there is a lacking 
of good evidence to show superiority or clear indication for its use 
(4). Yet a number of non-medical factors – hospital economics 
and marketing, surgeons’ desires to embrace technology, and 
even marketing by the maker of the surgical robot itself – seem 
to be playing a role in subscribers’ choice of robotic surgery.
HYSTeReCTOMY FOR BeNiGN DiSeASe
Robotic surgery has gained relatively rapid acceptance in benign 
hysterectomy in recent years (5). A 2013 JAMA study (6) reported 
that robotic hysterectomy increased almost 1,000% between 2007 
and 2010 – from 0.5 to 9.5% of all hysterectomies – while rates of 
laparoscopic hysterectomy increased much more slowly, from 24.3 
to 30.5%. Rates of robotic hysterectomy were higher in hospitals 
that had the da Vinci® robot, where they accounted for almost 
a quarter of hysterectomies. The overall complication rates were 
similar for robotically assisted and laparoscopic hysterectomies.
As for specific indications for robotic-assisted laparoscopic 
hysterectomy (RLH), potential benefit has been shown over 
conventional laparoscopy in obese women (7) and in case of 
large uteri (8–10). Reduced blood loss, decreased postoperative 
pain, and shorter hospital stay were associated with RLH com-
pared with vaginal hysterectomy, laparoscopic-assisted vaginal 
hysterectomy, and total laparoscopic hysterectomy. Furthermore, 
surgeon preference could be considered as another indication 
in US as many surgeons are not well trained in laparoscopy and 
vaginal route and may prefer robotics as it is easier to learn.
To date, there are still limited well-designed studies directly 
comparing outcomes and costs of conventional laparoscopic 
hysterectomy with RLH.
The largest retrospective study compared 100 patients treated 
by conventional laparoscopy hysterectomy before robotic adop-
tion with 100 patients with RLH: the mean operative time (skin to 
skin) 27 min longer in the RLH group (P < 0.001) (3, 11). Longer 
operative time was confirmed by Nezhat et al. (12). No difference 
in blood loss, length of stay, and postoperative complications 
were demonstrated.
The first published prospective study with 40 patients 
undergoing RLH (13) confirmed a longer operative time over 
conventional laparoscopy. Even if a slight longer hospital stay was 
observed statistically significant higher costs were found in RLH 
patients ($2,861 versus $5,410) in the laparoscopy group.
A randomized study by the same investigators analyzed out-
comes and costs of RLH versus laparoscopic hysterectomy in 95 
patients and found again a longer operative time for RLH (14). 
Even if a greater improvement in quality of life 6 weeks after RLH 
was shown over LSC, there was no difference in postoperative 
analgesic use or return to normal activities between the groups.
Most investigators consider higher costs per procedure sec-
ondary to lengthier operative time and disposable equipment. 
However, comparative trials can be biased by surgical experience, 
as operative times are usually shorter in procedures, in which 
surgeons are expert in comparison to procedures they are new to 
or they are learning.
Besides operative time and costs, some other technical concerns 
appear to potentially affect outcomes of RLH in a negative way.
First, vaginal cuff dehiscence is a serious complication of 
laparoscopic hysterectomy, and robotic assistance could be a 
major risk factor, possibly due to electrosurgical techniques or 
vaginal closure technique. In a systematic review (15), RLH is 
associated with a higher incidence of cuff dehiscence versus 
conventional laparoscopic hysterectomy (1.64 versus 0.64%). 
Judicious use of electrocautery at the vaginal cuff by blended cut-
ting electrosurgical current rather than coagulation current and 
the use of a two-layer cuff closure or bidirectional barbed suture 
are recommended to decrease the risk of vaginal cuff dehiscence. 
Second, the safety communication released by the US FDA in 
September 2014 (16) because of the risk of dissemination of undi-
agnosed uterine sarcoma in patients undergoing hysterectomies 
or myomectomies with power morcellation may decrease the rate 
of RLH and conventional laparoscopic hysterectomy in the US 
and Europe during the next few years, unless diagnostic tests for 
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uterine sarcoma improve or innovative devices are developed and 
deemed safe and effective for uterine power morcellation.
In summary, to date, evidence suggests no clear indications 
for RLH over other routes of minimally invasive hysterectomy for 
benign disease, for which robotics offer few surgical advantages 
over laparoscopy in the hands of experts in conventional laparos-
copy, at an increased cost. Insufficient data exist comparing robot-
ics to conventional laparoscopy in the hands of non-experienced 
surgeons. Many gynecologic surgeons who are not experienced 
in conventional laparoscopy are keen to adopt robotic surgery. 
Despite lacking of clear indications for use of robotics over other 
routes of minimally invasive hysterectomy (vaginal and conven-
tional laparoscopy), a great number of women could benefit from 
minimally invasive hysterectomy because the robot is an easy to 
learn, rapidly adopted, minimally invasive tool (5).
MYOMeCTOMY
Robotic myomectomy was developed and embraced by surgeons 
based on success laparoscopy had already achieved. The robotic 
approach has increased in popularity as it is a suture-intensive 
surgery, and assistance with robotic arms makes suturing simple 
and easy and allows surgeons with limited or no laparoscopic 
experience in suturing technique to perform the procedure in 
a minimally invasive way. However, there are a few limitations 
of robotic-assisted myomectomy, such as reduced field of vision 
and inability to apply torque, which makes removal of very large 
myomas difficult. Some authors recommend hybrid approach 
(conventional laparoscopy and robotic assistance) in case of 
myomas larger than 10 cm, beyond the pelvis, to preserve tactile 
sensation and avoid robotic equipment damage during traction 
and dissection (17). Lack of haptic feedback can cause breakage 
in suture material during suturing, but this can be overcome by 
increasing experience of the surgeon. Robotic approach may help 
surgeons to extend their boundaries in terms of size and number 
of myomas treated by minimally invasive techniques. However, 
superiority over laparoscopy has not been confirmed by data 
so far. In retrospective studies, robotic assistance seems to offer 
less blood loss and hospital stay but longer operative time when 
compared with conventional laparoscopy (18).
eNDOMeTRiOSiS
When performed by conventional laparoscopy, surgery for 
endometriosis is perhaps the most technically challenging in 
gynecology. The dense adhesions, the loss of function of adnexal 
structures, and the poor reproductive outcome put enormous pres-
sure of the surgeon to restore anatomy and function by removal 
of all endometriotic implants and improve patient’s quality of 
life (17). Robotic assistance may make this difficult task easier as 
a detailed and magnified 3D surgical view can greatly improve 
the quality of the surgical dissection in complex cases. However, 
published data are still sparse, and there is no solid evidence 
in literature to prove that. The largest series of robotic-assisted 
surgery for deep endometriosis has been published by Siesto et al. 
(19) in a retrospective cohort study showing neither significant 
intraoperative complications nor conversion to laparotomy. 
A retrospective study published by Nezhat et al. (20) evaluated 
78 patients with endometriosis and found a longer operative 
time but no significant difference in blood loss, hospital stay, and 
complications when compared with conventional laparoscopy. 
In summary, it seems robotic-assisted surgery does appear to be 
a feasible, safe alternative to achieve a comprehensive surgical 
treatment in endometriosis. However, outcome superiority to 
conventional laparoscopy is still to be demonstrated.
PeLviC ORGAN PROLAPSe RePAiR
Over the past two decades, minimally invasive surgery (MIS) 
abdominal surgery has increasingly been used to treat pelvic 
organ prolapse. Besides the several advantages associated with 
minimal invasiveness, this approach bridged the gap between the 
benefits of vaginal surgery with the surgical success rates of open 
abdominal procedures.
The most commonly performed procedure for suspension of 
the vaginal apex for postoperative vaginal prolapse by robotic-
assisted laparoscopy is the sacrocolpopexy (5). Conventional 
laparoscopic application of this procedure was first reported in 
1994 by Nezhat et al. and had not gained widespread adoption 
due to lengthy learning curve associated with laparoscopic 
suturing (21). Since FDA approval of the da Vinci® robot for 
gynecologic surgery in 2005, minimally invasive abdominal 
surgery for pelvic organ prolapse has become increasingly 
popular, as robotic-assisted laparoscopic sacrocolpopexy is an 
option for those surgeons without experience or training in the 
conventional route. At present, few randomized studies evaluated 
outcomes of robotic-assisted sacrocolpopexy versus conventional 
laparoscopy with robotic groups having longer operative times, 
short-term higher postoperative pain, and higher costs (22, 23). 
Complications, anatomical outcomes, and quality of life did not 
differ in general between the groups (23). Repair of pelvic organ 
prolapse can be performed robotically, and sometimes surgeons 
can feel suturing and exposure during the procedures less chal-
lenging with the assistance of the robot. However, even if robotic 
surgery may confer many benefits over conventional laparoscopy, 
these advantages should continue to be weighed against the cost 
of the technology. To date, as long-term outcomes, there is very 
little evidence about minimally invasive abdominal procedures 
for a repair of pelvic organ prolapse, and much more investiga-
tions are needed to evaluate subjective and objective outcomes, 
perioperative and postoperative adverse events, and costs associ-
ated with these procedures (5).
GYNeCOLOGiC ONCOLOGY
Since the da Vinci® surgical system approval in 2005 for use in 
gynecologic surgery, there has been a growing body of published 
reports evaluating the utility of robotic-assisted surgery in 
gynecologic oncology. Despite the well-known drawbacks associ-
ated with robotics and the fact that for many years the da Vinci® 
platform was not intended for simultaneous multiple quadrant 
surgery (new da Vinci Xi™ actually is), the technology has 
been widely adopted and has achieved considerable penetrance 
within the US gynecologic oncology surgeon community (24). 
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According to the Society of Gynecologic Oncology’s robotic task 
force position statement, robotic-assisted surgery has indeed 
“markedly changed” the practice patterns in the US gynecolo-
gist oncologist community (25). However, there is still no clear 
evidence whether robotic-assisted surgery is really superior to 
conventional laparoscopy in gynecologic oncology.
ROBOTiC-ASSiSTeD SURGeRY iN 
CeRviCAL CANCeR
Abdominal radical hysterectomy (ARH) has been the standard 
of care for patients with early disease (FIGO stage 1A2-2A). 
Laparoscopic approach of the procedure has been adopted 
by only a small number of surgeons because of its complexity. 
By contrast, radical hysterectomy can be made less challenging by 
robotic platform and can be considered as an ideal surgery for the 
adoption of the technology.
Multiple studies have evaluated the feasibility, the safety, and 
the outcomes of robotic-assisted radical hysterectomy (RRH). 
Comparative trials have demonstrated similar complications 
rates, improved operative outcomes, such as estimated blood loss 
and infections in the RRH groups, and variable operative times if 
compared with ARH and total laparoscopic radical hysterectomy 
(TLRH) (26–30). Moreover, it seems that the traditional laparo-
scopic radical hysterectomy experience is not required to use the 
robotic-assisted approach (26). Overall, intraoperative and post-
operative complications rate does not appear to be significantly 
different between RRH, TLRH, and ARH, and both minimally 
invasive approaches (RRH and TLRH) could be associated with 
fewer requirements in blood transfusions and a shorter hospital 
stay. Data on long-term outcomes in patients undergoing a RRH 
are sparse. However, equivalent disease-free recurrence rate 
appear to be equivalent in the RRH groups over after ARH 24 
and 48 months (95 and 97%, respectively) (31). Several reports 
have demonstrated that the number of lymph nodes retrieved is 
at least equal, if not larger, in RRH compared with traditional 
approaches (24).
ROBOTiC-ASSiSTeD SURGeRY  
iN eNDOMeTRiAL CANCeR
Endometrial cancer is the most common indication to use the 
robotic platform in gynecology oncology. MIS has become 
the accepted standard of care for endometrial cancer surgical 
staging. However, evidence from randomized clinical trials 
comparing robotic-assisted approach and conventional lapa-
roscopy is still lacking, and most data are form retrospectives 
studies. Benefits robotic technology over laparotomy appear 
evident in a large prospective trial published by Paley (32), 
where 377 patients undergoing robotic-assisted hysterectomy 
had much fewer serious complications, such as wound dehis-
cence, bleeding and urologic injury, and shorter length of 
stay at hospital when compared with 131 patients who had 
open surgery for the same indication. In a systematic review, 
Gaia et al. found less blood loss in robotic group versus con-
ventional laparoscopy (33). Interestingly, operative times for 
robotic-assisted surgery were similar to laparoscopy (219 ver-
sus 209 min, P = ns) but significantly longer than laparotomy 
(P < 0.005). The robotic approach can be challenging in case 
of lymphadenectomy when assessing of lymphatics above the 
level of the inferior mesenteric artery is required. However, 
the similar number of lymph nodes retrieved between robotic-
assisted surgery and laparotomy in several studies suggests that 
the concern does not translate into clinical practice. Benefits of 
robotic platform have been observed in trials evaluating out-
comes between surgical approaches in obese patients. When 
compared with laparotomy, Seamon et  al. (34) have demon-
strated that robotics had better wound complication rates (2 
versus 17%, odds ratio 0.10, CI95% 0.02–0.43, P = 0.002) and 
fewer major complications (11 versus 27%, OR 0.29, CI95% 
0.13–0.65, P  =  0.003) in obese patients with a body mass 
index (BMI) more than 35. Moreover, in a comparison trial 
published by Gehrig et al. (35), robotic-assisted surgery was 
associated with shorter operative time (P = 0.0004) and hospi-
tal stay (P = 0.001), higher lymph node count (P = 0.004), and 
less blood loss (P <  0.0001) over conventional laparoscopic 
approach in obese and morbidly obese patients undergoing 
endometrial cancer surgical staging.
ROBOTiC-ASSiSTeD SURGeRY iN 
OvARiAN CANCeR
The role of robotic surgery in ovarian cancer is not clear, as 
published data are still very sparse. Upper abdominal surgery is 
often required in advanced stages, and at present, the da Vinci® 
S and Si inability to access the pelvis and the upper quadrants 
simultaneously has been a major limiting factor to the use of the 
da Vinci® surgical platform in ovarian cancer. A retrospective 
review by Feuer et al. (36) evaluated surgical and postoperative 
outcomes in 63 patients undergoing robotic-assisted surgery for 
ovarian cancer. A longer operative time, less blood loss, and a 
shorter hospital stay were shown. Complication rates, lym-
phadenectomy yields, recurrence risk, and survival at 1 year did 
not differ between robotic-assisted surgery and laparotomy. To 
date, surgical centers using the robot for ovarian cancer usually 
perform surgery only in the setting of isolated recurrences or for 
diagnostic purposes. Nonetheless, capability to perform multi-
quadrant complex surgery is a major asset of the new da Vinci 
Xi™ surgical platform and could contribute to enhance spread of 
MIS in ovarian cancer patients in the next few years.
COSTS
In an era of shrinking reimbursements and added financial pres-
sures on hospitals, health-care cost has emerged as a major driv-
ing force for the adoption of surgical technology (24). The cost of 
ownership for a robotic surgery system depends heavily on the 
combined expenditure of the capital, consumables, and service 
contract. The current generation of robots costs over $1.5 million 
upfront, which is a considerable investment for most hospitals. 
Consumables costs can add an additional $1,500–$3,000 to each 
procedure, while service costs can be more than $140,000 per 
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year. Based on 150 procedures per year over a 5-year period, this 
translates to a cost of $4,450–$6,000 per patient. In addition to 
technology costs, training for both surgeons and clinical staff will 
also be a large item; training costs start at $20,000 per surgeon 
and can be higher depending on the skill level of the surgeon and 
the procedure. In addition, operating and recovery room time, 
hospital stay, time to return to work, and cost of readmission for 
complications should all be factored in (24, 37).
High utilization will be the key for a program to have posi-
tive margins. Very high volume programs typically perform 
200–380 procedures per system, per year, although 150–200 
procedures per year are normal for active programs. In many 
institutions, there are requirements put in place for minimum 
annual robotic case volumes to maintain privileges. If the insti-
tution purchases the platform, it must guarantee its use because 
of initial cash outlay and cost of upkeep. As previously stated, 
a number of trials have shown that robotic hysterectomies are 
more costly than laparoscopic hysterectomies. However, it is 
likely that cost would go down with decreased operative time 
and that operative time would go down with increased experi-
ence. In the present medico-economic climate, comparative 
cost has come under scrutiny with robotics due to the increased 
upfront cost but would actually be applicable for any technol-
ogy which is new (37).
As any emerging technology, costs will come down as a 
technology matures and competition enters the market. Next-
generation systems are expected to be priced more than $600,000, 
although some specialty robotic systems could be priced as low as 
$250,000. This reduction in price could allow providers perform-
ing 200 procedures per year to see margins of $1.3 million over a 
3-year period, which would make this technology very attractive 
to lower volume providers.
LeARNiNG CURve
Success in adoption of a surgical modality is highly dependent of 
the learning curve associated with acquisition of the necessary 
skills to comfortably and efficiently perform it. For the surgeon, 
robotic surgery overcomes some problems of conventional laparo-
scopic surgery. Muscular efforts are minimized because improved 
ergonomics when sitting at a console separate from the patient. 
Furthermore, combination of improved imaging and instrument 
control could allow for a faster surgical learning curve compared 
with conventional laparoscopy, which includes two-dimensional 
imaging and counterintuitive hand movements (38). However, 
even if the use of robot-assisted technology is believed to shorten 
the learning curve of complex minimally invasive procedures, it has 
not been fully demonstrated yet in literature. The number of cases 
required for proficiency in robotic-assisted gynecological surgery 
is not clear. One retrospective study evaluated robotic learning 
curves based on time for completion of the index gynecologic 
procedures (39). Investigators reported that times plateaued after 
50 cases. Lim et al. assessed the learning curve associated with 
performing the first 122 cases of robotic-assisted endometrial 
cancer surgical staging versus the first 122 procedures performed 
by laparoscopy (40). The authors demonstrated that 24 cases were 
required in the robotic arm before stabilization of the operative 
times occurred, whereas double that many were needed when 
procedures were performed by laparoscopy. Similarly, a second 
study showed that proficiency in robotic-assisted hysterectomy 
and lymphadenectomy for endometrial cancer were achieved 
after 20 cases (41). A more recent publication by Sandadi et al. 
evaluated the learning curve for completion of a robotic-assisted 
hysterectomy and showed that 33 cases were required before a 
fellow can be proficient in performing the procedure (42).
In summary, robotics may permit less experienced laparo-
scopic surgeons to perform minimally invasive procedures that 
previously would have required laparotomy. Factors that affect 
this learning curve include abdominal or laparoscopic experience 
with procedures being performed, prior laparoscopic skills of the 
surgeon, and the experience of the robotic surgical team. Training 
of the surgical team is essential and has been reported to decrease 
operative time and complication rates (38, 39, 43).
CReDeNTiALiNG AND TRAiNiNG
Currently, the optimal approach for training in robotic surgery 
remains undefined. Residents in US obstetric and gynecologic 
programs approved by the Accreditation Council for Graduate 
Medical Education are becoming trained in new minimally 
invasive technologies, with some residency programs instituting 
robotic training (38). The Council on Resident Education in 
Obstetrics and Gynecology is developing criteria for training 
in robot-assisted surgery. Intuitive Surgical is supporting the 
Robotic Training Network in a 50-site residency pilot program in 
gynecology. Training also is available at the fellowship level. The 
American Board of Obstetrics and Gynecology recommends that 
residency and fellowship programs serve an important role by 
ensuring their graduates maintain a balanced experience and that 
the introduction of robotic technology does not limit graduates’ 
competence in performing vaginal, laparoscopic, or abdominal 
hysterectomies. Surgeons should be skilled at abdominal and 
laparoscopic approaches for a specific procedure before under-
taking robotic approaches (38).
Hands-on training using the new technology is paramount. 
Animal subjects or human cadavers in a laboratory setting are 
useful. Most current robotic credentialing protocols require a 
live porcine lab. However, this training is expensive and time 
consuming, and for some, an ethical issue. As simulation capa-
bilities continue to improve, simulation centers will be able to 
assist greatly in initial training. Health-care institutions often 
require practitioners’ initial cases to be proctored by a surgeon 
experienced with this technology. In small institutions where an 
experienced proctor does not exist, other pathways may need to 
be considered.
In Europe, residency programs in gynecology very rarely 
include a structured robotic teaching and training, as most 
European robotic gynecologic surgeons still train “on the job.” 
Nonetheless, some research centers and university institutions 
offer a few days training courses to initiate surgeons to robotic 
technology. Noteworthy, School of Robotic Surgery at University 
of Nancy, France, offers an intensive course with national 
validation and a particular stress on simulation and surgical 
team training. Moreover, collaboration with Florida Hospital 
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Nicholson Center, Celebration, and Florida is currently under 
way to elaborate a standardized method for credentialing robotic 
surgery skills.
FUTURe DiReCTiONS
Global annual robotic revenues are currently approximately 
$4 billion and are expected to grow to $18 billion in 2018. To 
date, robotic surgery market is dominated by Intuitive Surgical 
monopoly, but more competition is welcomed by health-care 
providers in an effort to lower costs and improve efficacy and 
safety (37).
An increasing number of potential competitors are at different 
stages of development. Some have developed competitive plat-
forms for abdominal surgery based on a da Vinci® similar global 
architecture. Others are working on miniaturized platforms. 
What has been revealed concerning the potential of new robotic 
platforms is just the tip of the iceberg, as the major companies 
involved remain confidential about the real extent of robotic 
platforms (1).
In Italy, a new surgical platform (TELELAP ALF-X) has been 
developed by Italian research (SOFAR SPA) in collaboration with 
European Union (Joint Research Centre) and tested by gyneco-
logic oncology department at Gemelli University in Rome, 
where about 150 gynecological procedures (benign conditions 
and initial stages of gynecological cancers) have been performed 
with positive results. ALF_X consists of a surgeon console and 
a multiport robotic arm platform. Noteworthy, an advanced eye 
tracking system is used to control the endoscopic vision in three 
dimensions through sensors, which move the 3D high definition 
camera around the surgical field by following the surgeon’s eye 
movements. Moreover, the platform includes a haptic feedback 
system, reusable endoscopic instruments, and has already been 
certified for use in gynecology, urology, thoracic, and general 
surgery procedures in Europe, but upfront cost is still high at 
$1–$1.4 million (1, 37).
AVRA Surgical is a New York-based company currently devel-
oping the AVRA Surgical Robotic System (ASRS). The platform 
is configured to be modular with up to four arms and a wireless 
link between the surgeon’s console and the patient-side cart. 
Modularity could make the system more cost-effective and allows 
adapting to multiple surgical and image-guided percutaneous 
procedures.
Recently, Google and Johnson & Johnson have announced 
that they will team up to develop an advanced, robot-assisted 




Laparo-endoscopic single-site surgery (LESS) is a relatively new 
MIS technique aiming to reduce surgical trauma, as the abdomi-
nal cavity is reached through a single abdominal incision. The 
main difficulty in LESS is the lack of surgical triangulation giving 
no other option but to use a chopstick technique, and causing 
a continuous internal and external conflict between operating 
instruments and the optical instrument. Robotics could effectively 
overcome this problem with the ability to cross the instruments 
and simultaneously invert the control panel through software 
manipulation (1).
Intuitive Surgical has a dedicated platform enabling LESS, 
called da Vinci sp™ single port robot-assisted surgical system. 
The device delivers a 3D HD camera and three fully articulating 
instruments through its 25-mm cannula. While the FDA has 
already cleared the system for urologic procedures, the da Vinci 
sp™ Surgical System will not be released to the market till it will 
be totally compatible with the Xi platform.
Several snake-like robots are currently under development. 
The flexible architecture and multiple degrees of freedom make 
this concept the most suitable one for LESS.
One of most advanced and interesting projects is from 
Titan Medical (Toronto, ON, Canada), which is developing 
SPORT™ (Single Port Orifice Robotic Technology). The 
platform should be smaller and less bulky than da Vinci® 
and include a surgeon remote workstation and a robotic arm. 
The system is issued from IREP technology, which has been 
licensed to the company by Columbia University and consists 
of a 25-mm single access port containing two snake-like oper-
ating instruments (6-mm diameter) and a 3D-HD camera. The 
first targets of SPORT are gynecology, general and urology 
procedures, and it is expected to be commercially available in 
2016 in Europe and in 2017 in US at a price below $1 million. 
So far, the platform has demonstrated a high level of dexterity 
and controllability in an experimental setting and a porcine 
model. Moreover, the company recently signed an agreement 
with Anne Arundel Medical Center’s Innovation Center in 
Maryland to develop a comprehensive training program for 
the use of the platform (1, 37).
In Europe, a tele-robotic system [Single-access Transluminal 
Robotic Assistance for Surgeons (STRAS)] to perform LESS is 
currently under development in Strasbourg, France and includes 
a high-resolution camera, an intuitive haptic interface, and a 
visual tracking system (1).
iMAGe GUiDANCe
Real-time image guidance to complement robotically assisted 
procedures, through the concepts of augmented reality, may 
become the main revolution to increase safety and effective-
ness in MIS in the next years. During surgery, medical imaging 
(CT, MRI, or 4D ultrasonography) can be overlaid on real-time 
patient images, obtaining augmented reality which provides 
surgical navigation through a patient’s anatomy. At present, the 
main challenge in image guidance applied to soft tissue surgery 
is associated with the presence of patient’s respiratory movement 
and the deformation of soft tissues during surgical manipulation, 
as the perfect superimposition of real and computer-generated 
images is inaccurate when rigid model of mobile structures are 
used. To overcome that, a 3D image of the zone of interest is 
acquired in the operating room and can be updated at any time 
during surgery. Future innovations will likely conceive real-time 
MRI systems to obtain a real-time refresh of the patient model 
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with or without robotic assistance. It is easy to forecast a special 
interest of image guidance technologies in gynecologic oncology 
complex procedures (1).
CONCLUSiON
The magnified view, improved ergonomics, and dexterity offered 
by robotic platforms may facilitate the switch from open to MIS. 
To date, overall superiority of robotic technology over conven-
tional laparoscopy has not been demonstrated. However, selected 
procedures (gynecologic oncology, endometriosis, and microsur-
gical infertility procedures) might benefit from robotic assistance. 
Higher costs of robotic surgery are secondary to the Intuitive 
Surgical monopoly and are likely to decrease with future competi-
tors’ robotic platforms.
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